论文部分内容阅读
本实验用同位素掺入法研究了抗癌新药米托蒽醌与钙拮抗剂维拉帕米合用对人腺样囊性癌Acc-2细胞DNA及蛋白质合成的影响。发现无毒剂量的维拉帕米可以增强米托蒽醌对Acc-2细胞DNA和蛋白质合成的抑制作用,使米托蒽醌对Acc-2细胞DNA及蛋白质合成的IG_(50)值降低,合并用药后,米托蒽醌对Acc-2细胞DNA及蛋白质合成的IC_(50)值分别下降了69.8％和65.3％。表明米托蒽醌与维拉帕米合用可使前者显示出更强的抗癌活性。同时,本研究还发现,米托蒽醌佐以维拉帕米可增强对Acc—2细胞DNA复制模板的损伤。本实验从细胞大分子水平说明,有可能将钙拮抗剂维拉帕米作为米托蒽醌的增效剂应用于临床化疗,以提高疗效。
In this study, isotope incorporation was used to study the effect of combination of mitoxantrone and verapamil on the DNA and protein synthesis of human adenoid cystic carcinoma Acc-2 cells. We found that non-toxic dose of verapamil can enhance the inhibition of mitoxantrone on DNA and protein synthesis in Acc-2 cells, reduce the IG 50 value of mitoxantrone on DNA and protein synthesis of Acc-2 cells, After combined treatment, mitoxantrone decreased the IC 50 values of DNA and protein synthesis in Acc-2 cells by 69.8% and 65.3%, respectively. Show that mitoxantrone and verapamil combined can make the former show more anti-cancer activity. At the same time, this study also found that mitoxantrone with verapamil can enhance the Acc-2 cell DNA replication template damage. This experiment from the cell macromolecular level shows that it is possible that the calcium antagonist verapamil as a mitoxantrone synergist for clinical chemotherapy to improve the curative effect.